Latest Breaking News On - Investigational use - Page 4 : comparemela.com

Supira Medical s Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

/PRNewswire/ Supira Medical, Inc., a Shifamed portfolio company, announced today that the company s percutaneous ventricular assist device (pVAD) will be.

San franciscoUnited statesCarlos camposAlexandre abizaidNitin salunkeKatie arnoldGagan singhAzeem latibFabios brito jrAmr salahiehPrnewswire supira medical incMedtech innovation forumSupira medical incStructural heart interventions at montefiore health systemsCardiovascular therapeuticsSupira system

Shifamed Innovation Hub to be Prominently Featured at TCT 2023

Shifamed Innovation Hub to be Prominently Featured at TCT 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesAzeem latibMurali srivathsaPaul sorajjaGagan singhAmr salahiehNitin salunkeBrito jrJennie kimAlexandre abizaidMedtech innovation forumPrnewswire shifamedPaulo medical schoolHeart instituteYear anniversary of early feasibility program

Shifamed Innovation Hub to be Prominently Featured at TCT 2023

Shifamed Innovation Hub to be Prominently Featured at TCT 2023
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesNitin salunkePaul sorajjaAlexandre abizaidFabios brito jrGagan singhAzeem latibMurali srivathsaAmr salahiehCarlos camposJennie kimPrnewswire shifamedMedtech innovation forumPaulo medical schoolYear anniversary of early feasibility program

Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33 6 Months of Follow-Up with First-Line Use of RYBREVANT and Lazertinib Combination Therapy

CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a. | June 5, 2023

United statesHoon leeKiran patelSamsung medical centerClinical developmentJanssen researchYuhan corporationAmerican society of clinical oncologyJanssen biotech incSungkyunkwan university school of medicineDrug administrationJanssen pharmaceutical companiesJanssen research developmentClinical oncologyMedical centerUniversity school

New Long-Term Data from the CHRYSALIS Study Show Median

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive.

United statesRegion flamandeNoord hollandSouth koreaJanssen cilag gmbMartin vogelHoon leeKiran patelNational cancer instituteJanssen pharmaceutical companiesAmerican society of clinical oncologySamsung medical centerEuropean commissionExchange commissionYuhan corporationCompanies of johnson